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Renal  cell carcinoma  is a group  of  malignancies  arising  from  the  epithelium  of  the  renal  tubules.  The
pattern  of  somatic  mutations  in  kidney  tumors  has been  extensively  investigated.  In the  current  2004
WHO  classification,  the  molecular  background  of a renal  tumor  has become,  in addition  to histopathology,
a  major  criterion  for  tumor  classification.  The goal  of  this review  is to discuss  morphology  and  genetics
of  adult  renal  epithelial  cancer  included  in the  2004  WHO  classification  and  to  mention  renal  tumor
types,  which  are not  considered  in  the  current  WHO  classification.  Further,  pathologic  considerations
with  clinical  and  prognostic  implications  are  provided.
© 2012 Elsevier Ltd. All rights reserved.
1. The WHO  classification of renal cancer
The term renal cell cancer refers to a heterogeneous group of
cancers derived from renal tubular cells. In the last years, patho-
logical and basic cancer research has characterized different renal
tumor entities [1,2]. The current WHO  renal cancer classification
from 2004 combines morphological and genetic characteristics
and recognizes some variations of renal cancers with different
immunophenotypes or molecular changes with clinical implica-
tions [3] (Table 1). These tumor subtypes have different prognosis
[4,5] and the response to novel therapies maybe different [6].
Clear cell renal carcinoma is the most frequent renal tumor
subtype [7]. These tumors have a very vascular tumor stroma, fre-
quently resulting in hemorrhagic areas. The typical yellow tumor
surface is due to the lipid content of the cells; cholesterol, neu-
tral lipids and phospholipids are also abundant (Figs. 1 and 2).
Some clear cell renal cell carcinomas have a cystic appearance. This
may  be due to the presence of necrosis (pseudo-cysts). Presence of
tumor necrosis is associated with increased aggressive behavior of
the tumors. Some clear cell renal cancer form genuine neoplastic
cysts. Cases with complete cystic appearance and without a solid
tumoral component are defined as multilocular cystic renal cell car-
cinoma [8].  This subtype has an excellent prognosis and is regarded
a low-malignant carcinoma subtype of clear cell renal cancer. Sar-
comatoid changes can also occur in clear cell renal carcinoma and
is associated with poor prognosis [5,9]. Most renal cell carcinomas
have little inflammatory response, but sometimes an intense lym-
phocytic or neutrophilic infiltrate with natural killer cells is present
[10] and there is an association between a strong lymphocytic infil-
tration and worse outcome [11]. Clear cell renal cell carcinomas
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most commonly metastasize hematogeneously via the vena cava
primarily to the lung. Retrograde metastasis along the paraver-
tebral veins, the vena testicularis/vena ovarii, intra-renal veins or
along the ureter may  also be a route of metastasis. Clear cell renal
cell carcinoma is well known for its metastasis to unusual sites
and late metastasis, even after 10 years or more. All clear cell kid-
ney tumors are considered malignant tumors, independent of the
tumor size [3].
Papillary renal cell carcinomas comprise approximately 10% of
renal cell carcinoma [5,12,13]. The age distribution of papillary
renal cell carcinoma is similar to clear cell renal cell carcinoma with
reported mean age at presentation ranging from 50 to 65 years [14].
Papillary renal cell carcinomas frequently contain necrosis. In some
tumors, a pseudo-capsule is identified. Bilateral and multifocal
tumors are more common in papillary renal cell carcinoma than in
other renal malignancies. The histology is characterized by epithe-
lial cells forming papillae and tubules (Fig. 3). The tumor papillae
contain a delicate fibro-vascular core. Aggregates of macrophages
are frequently present. Psammoma  bodies are common. Two mor-
phological types of papillary renal cell carcinomas have been
described [15]. Type 1 tumors with papillae covered by small cells
with scanty cytoplasm (Fig. 3A). Type 2 tumor cells are often of
higher nuclear grade with eosinophilic cytoplasm and pseudo-
stratified nuclei (Fig. 3B). Type 1 tumors are more frequently
multifocal. Sarcomatoid differentiation is also seen in papillary
renal cell carcinoma and is associated with poor prognosis. Pap-
illary renal cell carcinomas entirely composed by oncocytes have
been described [16]. This subset of papillary tumors shows clinical-
pathologic features different from type 1 and type 2 papillary renal
cell carcinomas and has been proposed as a third group of papillary
renal tumors.
Chromophobe renal cell carcinoma accounts for approximately
5% of renal cancer. They have a better prognosis than clear cell
renal cancer [17,18]. Mortality is less than 10%. Rarely, sarcomatoid
1044-579X/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
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Fig. 1. Gross appearance of clear cell renal cancer. Bright yellow color in some areas
is  due to lipid and cholesterol content of tumor cells.
transformation does occur and is a diagnostic sign of poor prog-
nosis [19]. Cases of chromophobe renal cancer have documented
distant metastasis into lung, liver and pancreas. It has been sug-
gested that liver metastasis is more frequent in chromophobe renal
Fig. 2. Microscopic appearance of clear cell renal cancer with classic pattern resem-
bling vegetable cells.
Table 1
WHO  histological classification of RCC.
Clear cell renal cell carcinoma
Multilocular clear cell renal cell carcinoma
Papillary renal cell carcinoma
Chromophobe renal cell carcinoma
Carcinoma of the collecting ducts of Bellini
Renal medullary carcinoma
Xp11 translocation carcinomas
Carcinoma associated with neuroblastoma
Mucinous tubular and spindle cell carcinoma
Renal cell carcinoma, unclassified
Fig. 3. (A) Papillary renal cell cancer type 1. Tumor cells are relatively small and
cuboidal. There are some foam cells. (B) Papillary renal cell cancer type 2. Tumor
cells are larger with eosinophilic cytoplasm.
cancers than in other histological subtypes [20]. The cut surface of
chromophobe renal cell carcinoma appears homogeneously gray or
gray-brown (Fig. 4). The tumor is characterized by large polygonal
cells with reticulated cytoplasm and prominent cell membranes.
Some cells are irregular and multinucleated. Perinuclear halos are
common. A diagnostic hallmark is a diffuse cytoplasmic staining
reaction with hales colloidal iron staining [21]. The eosinophilic
variant of chromophobe renal carcinoma is purely composed of
eosinophilic cells. Electron microscopically, the cytoplasm is char-
acterized by glycogen deposits and numerous vesicles. The major
differential diagnosis of chromophobe renal carcinoma is renal
oncocytoma. Renal oncocytoma is considered to be a benign neo-
plasm [22]. It has been postulated that eosinophilic chromophobe
renal cell cancer originates from renal oncocytoma, and represents
the malignant form of this tumor. However, this hypothesis has not
been proven. The so-called hybrid tumors share histopathological
characteristics of chromophobe carcinoma and oncocytoma.
Collecting duct carcinoma is a very rare subtype of renal cell carci-
noma, accounting for about 1% of all renal cancer types. This tumor
type is extremely aggressive with frequent metastasis already at
presentation [23–25]. These tumors are usually located in the cen-
tral region of the kidney and have a gray-white appearance with
irregular borders. They often display infiltration of peri-renal and
renal sinus fat. Metastasis to regional lymph nodes, lung, liver, bone
and adrenal glands are comment. Histologically, collecting duct
cancer is characterized by a tubulo-papillary architecture with a
characteristic desmoplastic stroma reaction. Renal medullary carci-
noma is a rapidly growing tumor of the renal medulla associated
almost exclusively with sickle cell trait. This is an extremely rare
tumor. The majority of cases show sickled erythrocytes [26,27].
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Fig. 4. Gross appearance of chromophobe renal cancer. The tumor is well circumscribed and has a gray color.
Translocation carcinomas associated with Xp11.2 transloca-
tions/TFE3 gene fusions are characterized by different translocations
involving chromosome Xp11.2, resulting in gene fusions involv-
ing the TFE3 gene. Meanwhile, different fusions are identified,
including the t(X;1)(p11.2; q21) fusion, the t(X; 17)(p11.2;q25),
which results in fusion of the ASPL and TFE3 genes and the
t(X;1)(p11.2;q34), resulting in fusion of the PSF and TFE3 genes
as well as other fusions [28–31].  Translocation carcinomas pre-
dominantly affect children and young adults [32]. However,
translocation carcinomas also occur in older patients [33]. Histo-
logically, translocation carcinomas have a papillary architecture
comprised of clear cells with voluminous clear to eosinophilic
cytoplasm. Psammoma  bodies can be present. The immunopro-
file is characterized by nuclear immunoreactivity for TFE3 protein.
Only 50% express epithelial markers such a cytokeratin and EMA
by immunohistochemistry. In adults, translocation carcinomas are
associated with poor prognosis, presenting at advanced stages, fre-
quently with lymph node metastasis at diagnosis.
Renal cell carcinoma after neuroblastoma are seen in long
term survivors of childhood neuroblastoma [34]. Therefore it has
been suggested that therapy for neuroblastoma plays a role in
the pathogenesis of these renal carcinomas. These tumors are
Fig. 5. Typical microscopic appearance of mucinous tubular and spindle cell carci-
noma showing low-grade spindle cell areas and stromal mucin.
morphologically heterogeneous with solid and papillary architec-
ture and cells with eosinophilic cytoplasm.
Mucinous tubular and spindle cell carcinomas are low-grade renal
epithelial neoplasms with tubular and spindle cell features and
mucinous stroma [35,36]. They usually present as asymptomatic
masses. The prognosis is favorable in most cases (Fig. 5).
Renal cell carcinoma, unclassified is a term for a renal cancer case,
which is not defined in the current WHO  classification. This group
represents less than 5% of all renal cell carcinomas. Most of these
cases have sarcomatoid morphology without recognizable epithe-
lial elements, mucin production or unrecognizable cell types [37].
Since there is no evidence that renal tumors arise de novo as sarco-
matoid carcinomas, this type is not viewed as a type of its own. Most
unclassified RCC are associated with a highly aggressive biological
behavior and poor clinical outcome.
2. Renal cancer subtypes – not yet considered in the WHO
classification
Tubulocystic carcinomas are tumors composed by tubules and
cysts lined by cuboidal or hobnail cells with eosinophilic cytoplasm
and large nuclei showing prominent nucleoli [38]. These tumors
have a characteristic macroscopy with a white or a gray spongy cut
surface. Most of these cases are early stage tumors. The histogene-
sis of tubulocystic carcinoma is unclear. It has been suggested that
tubulocystic carcinoma my  represent a subset of papillary renal cell
carcinoma or collecting duct cancer. Due to their specific patholog-
ical images, this type of RCC should be included as a distinct tumor
entity in a future WHO  classification.
Thyroid-like renal carcinoma is a renal carcinoma with a follic-
ular architecture resembling follicular carcinoma of the thyroid
[39]. The tumors are composed of cells showing low-grade pleo-
morphism with eosinophilic cytoplasm. Metastasis from a primary
thyroid follicular carcinoma has to be excluded and TTF1 expres-
sion as a marker of thyroid carcinoma should always be undertaken
in tumors showing this morphology to exclude metastatic disease.
Acquired cystic disease-associated renal cell carcinomas are
tumors associated with end-stage renal disease. In end-stage renal
disease, all renal cancer subtypes are found [40]. Specific subtypes
include acquired cystic disease-associated renal cancer with pres-
ence of oxalate crystals and large eosinophilic cells with rounded
Author's personal copy
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nucleus and large nucleolus. The second type is the clear cell pap-
illary renal carcinoma. This tumor is characterized by cells with
clear cytoplasm and low-grade nuclear pleomorphism, frequently
with a dominant cystic component. Clear cell papillary RCC fre-
quently contain a prominent pseudocapsule. This type can also be
seen in kidneys both with or without acquired cystic disease and is
characterized by a good prognosis [37].
Leiomyomatous renal cell carcinomas are composed of tubular
aggregates of neoplastic clear cells intermixed with a prominent
leiomyomatous proliferation [37]. The smooth muscle component
is often more pronounced at the periphery. There is currently a
debate regarding the relationship between clear cell papillary RCC
and leiomyomatous renal cell carcinoma. A relationship to clear
cell renal cancer appears possible. Clear cell papillary renal cell
carcinoma may  also show overlapping morphological features to
leiomyomatous renal cell carcinoma. Therefore, a formal classifica-
tion is early.
3. Hereditary renal cell carcinoma
Almost all renal cell tumor types occur in a sporadic or in a
hereditary form [41]. Usually, affected patients develop bilateral
or multiple renal tumors. Within the last years, a number of hered-
itary tumor syndromes with predisposition to the development of
renal cell carcinoma have been identified. The molecular analy-
sis of tumor tissue in mutation carriers with renal and extrarenal
neoplastic manifestations has led to the identification of the pre-
disposing genes. These genes include VHL, MET, FH,  BHD and
HRPT2 (Table 2). The hereditary renal cell carcinoma syndromes
are extremely rare. VHL disease is the most frequent familial renal
cancer syndrome and is associated with clear cell renal carcinoma,
escorted by mutations in the VHL gene and loss of the wild-type
VHL (see Section 3) [42]. Patients with hereditary papillary renal
cell carcinoma syndrome have multiple, bilateral papillary renal
cell carcinomas with papillary type 1 histology. The patients have a
germ line activating mutation in the MET  proto-oncogene [43,44].
Papillary type-2 renal carcinomas and uterine smooth mus-
cle tumors are associated with hereditary leiomyomatosis and
renal cell cancer syndromes (HLRCC), which is caused by germ
line loss-of-function mutations in the fumarate hydratase (FH)
gene. The hyperparathyreoidism-jaw tumor (HPT-JT) syndrome is
associated with parathyroid adenomas, fibro-myalgeous tumors
of the jaw and renal tumors. This syndrome is caused by germ
line mutations in the HRPT2 gene [45,46].  The Birt–Hogg–Dubé
(BHD) syndrome is associated with an increased risk for renal
cancers, especially for chromophobe renal cell carcinomas and
oncocytomas [47,48]. In some cases, so-called oncocystic hybrid
tumors are seen. Tumors can be multiple and bilateral. The skin
tumors include fibrofolliculomas, trichodiscomas and acrochordo-
mas. Spontaneous pneumothorax and the presence of pulmonal
cysts are recognized features of the BHD syndrome. The BHD gene
maps to chromosome 17p11.2. Multiple, unilateral or bilateral clear
cell renal cell carcinomas are found in the constitutional transloca-
tion of chromosome 3. Affected family members carry a balanced
chromosome translocation, involving chromosome 3.
4. Cytogenetic and molecular alterations in renal cell
carcinomas subtypes
The pattern of somatic mutations in kidney tumors has been
extensively investigated and has become a major criterion for clas-
sification [1]. Chromosome 3p deletion (LOH 3p) is the most typical
genetic abnormality in sporadic clear cell renal cell carcinoma and is
regarded as an important step in tumor initiation. Different genes
have been located on the short arm of chromosome 3 which are
probably involved in renal carcinoma. One of them is the von
Hippel–Lindau disease tumor suppressor gene in 3p25-26 [49,50].
Other putative genes at 3p are PBRM1 [51], RASSF1a [52] and NRC-1
[53]. The consequences of the mutations of the VHL gene are dis-
cussed in Sections 3 and 6. Recently, mutations of the VHL gene
have been reported in multilocular cystic renal cell carcinoma and
confirm the hypothesis that multilocular cystic renal cell carcinoma
represent a subtype of clear cell renal cancer [54]. The relationship
of leiomyomatous renal cell carcinoma and clear cell papillary renal
cancer based on the presence or absence of VHL mutation and/or 3p
losses is currently controversial. Apart from the VHL inactivation as
an initiating event in clear cell renal cancer, many different genetic
alterations have been reported for this tumor type, some of them
associated with prognosis [55–67].
Papillary renal cell carcinoma is characterized by tri-
somy/polysomy of chromosomes 3q, 7, 8, 12, 16, 17 and 20
and loss of the Y-chromosome [68,69]. The c-met proto-oncogene
mutation on chromosome 7 characterizes hereditary papillary
renal cell carcinomas but is rare in sporadic papillary renal cell
carcinoma [44,43].
Karyotyping, fluorescence and in situ hybridization and com-
parative genomic hybridization revealed that multiple and
non-random chromosomal losses of chromosomes 1, 2, 6, 10, 13, 17,
21 and the Y or X chromosomes are frequent in chromophobe renal
cancer, whereas renal oncocytomas have only rearrangements or
translocations involving 11q13 or partial losses of chromosomes
1, 14 and sex chromosomes [70]. In contrast, loss of the short arm
of the chromosome 3 is rare [71]. In collecting duct cancer, tri-
somy/polysomy for chromosomes 4, 7, 8, 17 and 20 and loss of
chromosomes 14, 18 and 22 were reported [72]. Also, loss of other
chromosomes has been described. In mucinous tubular and spindle
cell carcinoma, losses involving chromosomes 1, 4, 6, 8, 13, 14 and
15 and gains of most other chromosomes have been reported [73].
However, most of these tumors also show the gains of chromosome
7 and 17 that are typically found in papillary renal cell carcino-
mas. As mentioned above, translocation carcinomas are defined
by Xp11.2 translocations resulting in TFE3 gene fusions. Gene
expression profiling and fluorescence in situ hybridizations studies
indicate that tubulocystic carcinomas have gains of chromosome 7
and 17, supporting the hypothesis that these tumors represent a
subset of papillary renal cell carcinoma [38,74,75]. In thyreoid-like
renal cell carcinomas a widespread under- or over-expression of
genes, particularly involving chromosomes 1, 2, 3, 5, 6, 10, 11, 16
and 17 is present [39]. In acquired cystic disease-associated RCC’s,
multiple gains of numerous chromosomes, including chromosomes
1, 2, 6, 10, 3, 7, 17 and Y where seen [76]. Mutations of the VHL
gene have not yet been identified in these tumors. Clear cell papil-
lary RCC did not show 3p losses or trisomy of chromosome 7 and
17. Therefore, the potential relationship of these tumors to other
tumor entities is unclear. Genetic studies on leiomyomatus renal
cell carcinomas are controversial. In some cases, loss of chromo-
some 3 has been reported. In other studies, there was  no evidence
of 3p deletion in the 3 cases examined [37].
5. The cell of origin in renal cell cancer?
Renal cancer a heterogeneous tumors, which may be derived
from specific cells within the nephron and collecting ducts. Based
on older immunohistochemical analyses, it has been suggested that
clear cell and papillary renal cell carcinomas are derived from the
proximal tubules [77], chromophobe renal cancer and oncocytoma
from the distal nephron [17] and collecting duct cancer from the
ducts of Bellini [17,78–80].  It was  tempting to speculate that muci-
nous tubular and spindle cell carcinoma are derived from the loop
of Henle [73], and tubulocystic carcinoma also from the collecting
Author's personal copy
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Table 2
Hereditary renal cell tumors.
Syndrome Chr. Gene Protein Tumor type Extrarenal manifestations
Dermis Other organs
von Hippel–Lindau 3p25 VHL pVHL Multiple, bilateral clear cell RCC,
renal cysts
– Hemangioblastoma of retina/cns;
pheochromocytoma;
pancreatic-/renal cysts;
neuroendocrine tumors;
epididymal/parametrial cysts;
tumors of the inner ear
Hereditary papillary
RCC
7p31 c-MET HGF-R Multiple, bilateral papillary RCC
(type 1)
– –
HLRC 1q42 FH FH Papillary RCC (non-type 1) Leiomyoma Uterine
leiomyoma/leiomyosarcoma
Familiary papillary
thyroid carcinoma
1q21 ? ? Papillary RCC oncocytomas – Papillary thyroid carcinoma
Hyperpara –
thyroidism – jaw
tumor syndrome
(HP-JT)
1q25 HRPT2 Epithelial–stromal mixed tumors,
papillary RCC
– Tumors of the parathyroidea;
fibro-osseous jaw tumors
Birt–Hogg–Dubé 17p11 BHD Folliculin Multiple chromophobe RCC,
oncocytoma, papillary RCC
Facial fibrofolliculoma Pulmonal cysts; spontaneous
pneumothorax
Tuberous
Sclerosis
9q34
16p13
TSC  1
TSC 2
Hamartin
Tubertin
Multiple, bilateral
angiomyolipomas,
lymphangioleiomyo-matosis;
Rare clear cell RCC
Angio-fibroma:
subungual fibroma
Cardiac rhabdomyoma;
adenomatous small intestine
polyps; pulmonal/renal cysts;
cortical tuber; subependymal giant
cell astrocytomas
Constitutional
translocation chr.3
3p13-
14
? ? Multiple, bilateral clear cell RCC – –
tubules or proximal tubules. However, this model is recently chal-
lenged. Mandriota et al. have shown that CA-9 expression, a specific
read out for HIF activation can be seen in cells of the proximal as
well as distal nephron [81]. CA-9 positive single cells are regarded
as precursor legions of clear cell renal cell carcinomas in VHL syn-
drome. Recently, it has been shown that such CA9-positive cells
have VHL-deletions in cystic lesions of patients with VHL-disease
[82]. Therefore, a model of a cyst-dependent renal cell carcinoma
pathway in VHL disease and a potential cyst-independent pro-
gression pathway in sporadic renal cell carcinoma was proposed
[83–85]. These progression pathways are potentially independent
of the position within the nephron. The relevance of renal stem cells
as cell of origin for renal cell carcinoma is discussed in Section 6.
6. Prognosis of renal cell carcinoma and the use of
biomarkers
The biological behavior of renal cell carcinoma is unpredictable
by histology alone. At the moment, the most accepted prognostic
factors are tumor stage and the histological differentiation grade.
The correct pathological staging is the basis for every clinical deci-
sion [86]. In the last years, it has been demonstrated that invasion
of the sinus fat tissue is more frequent than expected and is asso-
ciated with greater tumor aggressiveness [87–89].  This sinus fat
tissue contains a number of large thin-walled veins and lymphatics
and it is not separated from the renal cortex by a fibrous capsule.
The most accepted grading system is Fuhrman’s grade, which
was applied to all renal cancer subtypes [90] and represents the
most accepted prognostic parameter. Recently, some criticism
appears in the use of Fuhrman grading system in RCC of the non-
clear cell types [91]. Fuhrman’s grading seems not to be appropriate
to grade chromophobe renal cancer and other grading systems have
been recently proposed to better predict prognosis of this tumor
type [92,93].  In addition, mucinous tubular and spindle cell carci-
noma is not graded. Likewise, the oncocytoma is a benign tumor
and should not be graded.
In addition to Fuhrman’s grade and tumor stage, multiple renal
cell biomarkers have been studied in the last years [94]. Molec-
ular events that are involved in renal cancer pathogenesis may
influence the clinical behavior of renal cell carcinoma and may help
in improving individualized prognostication and risk-stratified
clinical decision making. The molecular dissection of renal cell can-
cer by gene expression studies has increased our understanding of
the pathways that are altered in renal cancer cells, leading to plenty
potential renal cancer biomarkers [95,96]. However, there are no
useful clinical or pathological biomarkers at the moment, which
are routinely used in the prognostication of renal cell carcinoma
or in the prediction of the response to novel targeted drugs. Addi-
tional biomarker may  have some added value when incorporating
within existing prognostic models, but the potential for improv-
ing the predictive and/or prognostic ability is limited. Most of the
molecular biomarkers are associated with other established clinical
and/or pathological characteristics of renal cell cancer and are parts
of the VHL/HIF-signaling pathway [97–99]. Therefore, the value of
novel markers has to be proofed within the framework of existing
models [100]. In the future, the probability of response to targeted
therapy represents an important field in RCC research.
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